Loading organizations...
Pangu Venture Capital functions as an investment firm, deploying capital into early-stage enterprises across several high-growth technological and cultural sectors. It specializes in supporting companies innovating within the Internet, life sciences, cleantech, artificial intelligence, and culture industries. The firm provides strategic funding to accelerate the development of groundbreaking technologies and sustainable business models.
The firm was established to meet the evolving capital needs of specialized, rapidly growing markets. It emerged from the understanding that focused investment and strategic guidance are crucial for innovators impacting their respective fields. This inception reflects a commitment to empowering entrepreneurial endeavors within emerging industries.
Pangu Venture Capital primarily partners with founders and early-stage companies seeking strategic capital and guidance. Its vision centers on fostering innovation by empowering enterprises that develop solutions for critical global challenges and shape future industries. The firm cultivates a portfolio of resilient companies, aiming for both financial returns and meaningful societal impact.
Pangu Capital has 2 tracked investments across 2 companies. The latest tracked deal is $27.0M Series A Extension in Elixiron Immunotherapeutics in August 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 23, 2021 | Elixiron Immunotherapeutics | $27.0M Series A Extension | Pangu Capital | CDIB Capital Group, Daiwa Corporate Investment, Fubon Ventures, Hong TAI Electric Industrial, Mega International Commercial Bank |
| May 5, 2021 | BridGene Biosciences | $12.0M Series A | Leilei Wang | Kaitai Capital, Takeda Ventures |